All posts by imreal

Olaris, Inc. to present data on metabolomic changes observed during DCD heart perfusion prior to successful transplant at the American Transplant Congress 2023 Meeting


We believe that this is another example of how metabolomics coupled with the Olaris CEREBRO platform can be used to benefit patients, expand access to lifesaving treatments, and allow for better treatment decisions and outcomes.

Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company’s study on the metabolic changes occurring in donor hearts after Donation after Circulatory Death (DCD) heart transplant has been selected for a poster presentation on June 5th at the upcoming American Transplant Congress (ATC) 2023 Annual Meeting, to be held June 3rd-7th in San Diego, CA.

The ATC 2023 presentation will describe data from a multi-year collaboration between Olaris and an elite team of heart transplant surgeons and researchers at Massachusetts General Hospital, including Drs. Seyed Alireza Rabi, and Asishana Osho. The collaboration was formed with the goal of identifying biomarkers of heart damage due to ischemia and reperfusion during DCD heart transplant. DCD followed by ex vivo machine perfusion, in which organs are procured following circulatory death and placed on a machine to maintain viable status before transplant, represents a new method in heart transplant. Currently, over 3,000 Americans on the heart transplant waiting list each year are unable to access life-saving transplants due to a shortage in donor organs; using DCD for heart transplant has the potential to increase the number of available organs by over 30%, but improved measurements of heart quality are needed to improve DCD outcomes.

“Discovering biomarkers to aid us in maximizing the identification of appropriate hearts for transplant will be crucial to allow DCD to reach its full potential. The research that is ongoing at MGH and Olaris represents an exciting step forward in that direction,” said Dr. David D’Alessandro, the Surgical Director of Heart Transplantation and Ventricular Assist Devices at MGH.

To better understand the changes occurring in the heart during DCD transplant, Olaris’ researchers examined changes in metabolites in 19 hearts during the DCD process, comparing metabolite levels after heart procurement to those after hours of machine perfusion. They found that several metabolites were consistently altered over time, reflecting metabolic reprogramming in the DCD hearts during machine perfusion. The results of the study identify metabolites and metabolic pathways which could be targeted for therapeutic benefit to preserve heart quality during perfusion or provide novel biomarkers of DCD heart quality for transplant decision-making.

“We are very excited by the data coming out of the study we performed with our partners at MGH. We believe that this is another example of how metabolomics coupled with the Olaris CEREBRO platform can be used to benefit patients, expand access to lifesaving treatments, and allow for better treatment decisions and outcomes,” said Dr. Elizabeth O’Day, CEO and Founder of Olaris.

For more information on the ATC meeting or to view the Olaris presentation during the conference, visit https://atcmeeting.org/. The presentation will be made available on Olaris’ website at http://www.myolaris.com/news following the conference.

About Olaris

Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/

Share article on social media or email:

Dr. Gary Frishman of Boston IVF Named A 2023 Top Fertility Doctor in Rhode Island


“For over 30 years, Dr. Frishman has been recognized by his peers and respected by his patients for delivering a sustained level of superior reproductive care.” — David Stern, CEO of the Boston IVF fertility network.

Boston IVF, a worldwide leader of fertility treatment and family building, is pleased to announce that reproductive endocrinologist Gary N. Frishman, MD(he/him) has been selected by Rhode Island Monthly as a 2023 Top Fertility Doctor in Rhode Island.

Dr. Frishman has been named a Top Fertility Doctor in every Rhode Island Monthly’s Top Doctor article since the award’s inception in 1992.

Rhode Island Monthly’s Top Doctors are elected through a highly competitive peer selection process, with Rhode Island licensed physicians and clinicians selecting the most experienced, trustworthy, and empathetic candidates across 50 specialties.

Dr. Frishman, a double board-certified reproductive endocrinologist at Boston IVF, treats individuals and couples alongside fellow reproductive endocrinologist Kerri Luzzo, MD at the fertility network’s new, state-of-the-art IVF center in Providence, RI (148 W River Street #6).

Boston IVF’s new fertility center in Providence offers 10,000+ square feet of treatment space, on-site IVF, IUI, egg freezing, cycle monitoring, and more.

“Having children is one of the greatest privileges and experiences in life,” said Dr. Frishman. “I chose this field to help my patients achieve this dream.”

Alongside his Rhode Island Monthly recognition, Dr. Frishman has earned national and international acknowledgment for his contributions to Women’s Health. He has received numerous teaching awards from Brown University, the American College of Obstetricians and Gynecologists (ACOG), the Council on Resident Education in Obstetrics and Gynecology (CREOG), and the Association of Professors of Gynecology and Obstetrics (APGO), amongst others.

“For over 30 years, Dr. Frishman has been recognized by his peers and respected by his patients for delivering a sustained level of superior reproductive care,” said David Stern, CEO of the Boston IVF fertility network.

Dr. Frishman is an active member in several surgical societies —including the American Society for Reproductive Medicine (ASRM) — and served as president for both the Society for Reproductive Surgeons and the American Association of Gynecologic Laparoscopists (AAGL). Furthermore, he has held positions for internationally renowned journals such as The Obstetrician and Gynaecologist and the Journal of Minimally Invasive Gynecology.

A long-time Rhode Island resident, Dr. Frishman is also a Clinical Professor of OB/GYN at Brown University’s Warren Alpert Medical School, where he teaches the next generation of fertility doctors. Additionally, he has served on the boards of Big Sisters of Rhode Island, Day One Rhode Island, City Year Providence, and Rhode Island Blood Center’s Advocacy Board.

To learn more about Dr. Frishman, to receive fertility treatment advice, or to schedule a consultation, visit Boston IVF’s website for more information.

Follow Boston IVF on Instagram

Follow Boston IVF on Linkedin

Follow Boston IVF on Facebook

Follow Boston IVF on Twitter

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email:



OneStaff Medical Welcomes New Chief Financial Officer, Mike Vaughn


We are beyond excited to put a proven leader, like Mike, in a position to further evolve what we are doing here

OneStaff Medical, an independently-owned, Omaha-based travel nurse staffing agency, recently hired Mike Vaughn in a new Chief Financial Officer (CFO) role.

Vaughn, with over 25 years of finance and business experience with a heavy focus on international operations, is being tasked with leading their finance department and evolving its operations to meet the demand from the previous couple years of rapid growth. Vaughn’s vision is to help position the company for continued success in the competitive Travel Nurse Staffing industry.

“We are beyond excited to put a proven leader, like Mike, in a position to further evolve what we are doing here,” Andrew Wettengel, Director of Marketing, said. “With his extensive experience within Finance, and successful track record, he is an obvious fit to enhance our ability to drive the next stage of our company’s growth in that department.”

OneStaff Medical provides temporary staffing solutions for healthcare facilities across the country. The 2023 year will be a pivotal year for the industry, in an already competitive marketplace, as pay rates and market fluctuations are leveling back out post COVID, “Travel Nursing Payrate Predictions for 2023”. The COVID crisis has only helped further solidify agencies, like OneStaff, as crucial staffing partners to healthcare facilities across the country.

About OneStaff Medical

Headquartered in Omaha, OneStaff Medical was founded in 2010 as a Travel Nursing staffing firm and has consistently been honored as one of SIA’s “Best Staffing Firms to Work For,” as well as made the “2022 Fastest-Growing US Staffing Firms” list. In the past few years, OneStaff also added Eldercare, Allied, and Surgery travel staffing divisions to their portfolio of services. In addition to their Omaha office, they opened a Columbus, OH office in 2020, as well as a Clearwater, FL office in 2021, and continue to look towards expanding as one of the few proudly independently-owned Travel Nurse staffing firms in the country.

Share article on social media or email:

Boston IVF Welcomes Reproductive Endocrinologist Dr. Jill Attaman to Expanding New Hampshire Fertility Center Physician Team


“New Hampshire patients and Boston IVF have gained an accomplished and dedicated reproductive endocrinologist in Dr. Attaman.” — David Stern, CEO of the Boston IVF fertility network.

Boston IVF, one of the world’s most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986 and is known for achieving high IVF success rates, is pleased to announce the addition of reproductive endocrinologist, Jill Attaman, MD to its practice and physician team. Dr. Attaman is now accepting new patients at Boston IVF’s fertility center in Bedford, New Hampshire.

Boston IVF’s fertility center in New Hampshire, the only IVF center in the state, hosts a state-of-the-art embryology laboratory, 15,000+ square feet of treatment space, and an enhanced team dedicated to superior patient care.

Dr. Attaman specializes in a comprehensive array of infertility treatments and family building services, including, intrauterine insemination (IUI), in vitro fertilization (IVF), egg freezing, LGBTQ+ family building services, recurrent pregnancy loss, PCOS, and more.

A long-time staple of fertility treatment and care in New England, Dr. Attaman arrives at Boston IVF from a prestigious Downtown Boston hospital, where as Director of the IVF Unit, she led the organization’s assisted reproductive care program, acted as Chair of Quality Assurance for the Division of Reproductive Endocrinology and Infertility (REI), and guided its OB/GYN transgender healthcare efforts.

“I am thrilled to join a practice as renowned as Boston IVF, where I can help provide family building treatments to a New Hampshire community which deserves local access to high-quality care,” said Dr. Jill Attaman. “My patient care philosophy aligns perfectly with Boston IVF, which values respect, empathy, support, education, and so much more.”

Alongside her role as a fertility doctor, Dr. Attaman has served as an assistant professor at the Geisel School of Medicine at Dartmouth College in Hanover, NH and is a clinical instructor at Harvard Medical School.

“New Hampshire patients and Boston IVF have gained an accomplished and dedicated reproductive endocrinologist in Dr. Attaman,” said David Stern, CEO of the Boston IVF fertility network. “We’re excited to be able to add Dr. Attaman to our outstanding clinical team in Bedford. Individuals and couples throughout New Hampshire who wish to build a family through fertility and family building treatments now have yet another amazing fertility expert whom they may turn to for care.”

Double-board certified in OB/GYN and REI, Dr. Attaman earned her medical degree at Michigan State University, completed her residency in Obstetrics and Gynecology at The Ohio State University Medical Center, and received her fellowship in Reproductive Endocrinology at Massachusetts General Hospital.

To learn more about Dr. Attaman, to receive fertility treatment advice, or to schedule a consultation, visit Boston IVF’s website for more information.

Follow Boston IVF on Instagram

Follow Boston IVF on Linkedin

Follow Boston IVF on Facebook

Follow Boston IVF on Twitter

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email:



IMCO focuses on “We in 23” at the 2023 National Convention


IMCO, the nation’s premier association of Independent Medical Distributors, wrapped up its 2023 Annual Convention and Trade Show last month at the Hilton Orlando in Orlando, Florida. “We in ‘23 is our Convention theme this year, focusing on the spirit of how we work together as individual companies within our collective group. The way we each achieve success may be measured differently, but as we work together collaboratively, our success is multiplied exponentially.” said IMCO CEO Bill McLaughlin. “The ever growing success of this annual event is a testament to the strength of our community and the true power ‘We’ hold.”

Our education sessions featured impactful speakers including Colette Carlson, a renown Certified Speaking Professional who has more than 20 years of experience helping individuals change behaviors that impact their success, Mike Marks of Indian River Consulting and many sales training and industry experts such as Al Bates of Distribution Performance Project and Mark Shonka of IMPAX Sales Performance. This event also included powerful distributor panels and roundtable discussions, a full-day trade show, valuable networking, and a Bootleggers Ball in true 20s fashion to end our time together.

Our 2022 Vendor of the Year was awarded to DUKAL. Members valued their “strategic partnership” and support and flexibility in the field alongside the substantial growth seen throughout this year.

About IMCO

IMCO was founded in 1981 to unite independent medical supply distributors and provide them the same purchasing and marketing power as large national medical supply distribution companies. Today, IMCO is the premier association for independent medical supply distributors that are dedicated to remaining independent. IMCO Members operate in Primary Care, Extended Care, Acute Care, Home Care, Emergency Medical Services, Veterinary, Industrial Safety, Dental, Lab and many other specialized classes of trade.

Follow IMCO on Facebook at https://www.facebook.com/IMCOInc

Connect with IMCO on LinkedIn at https://www.linkedin.com/company/2267829/

See more at IMCOInc.com

Share article on social media or email:

Newly Established Medical and Public Health Laboratory Coalition to Tackle Workforce Shortages


Laboratory professionals serve critical roles in our nation’s health systems, as highlighted during this pandemic. These can be excellent career opportunities. We need to ensure these opportunities are known and accessible for all individuals. Bianca Frogner, PhD

The medical and public health laboratory workforce that underpins the U.S. healthcare system is currently experiencing a personnel shortage. A significant number of laboratory professionals—experts at performing patient laboratory testing—have left the workforce due to retirement, others because of the burnout from the COVID-19 pandemic. On top of this, many accredited training programs have closed. As a result, the number of qualified laboratory professionals has rapidly declined, and this has the potential to disrupt the delivery of high-quality patient care. To address this trend, the Medical and Public Health Laboratory Workforce Coalition—a coalition of more than 20 national and regional laboratory, pathology, and other healthcare associations—has formed to work toward building a robust, more diverse medical laboratory workforce.

Medical and public health laboratory professionals are critical to quality patient care, with many, if not most, medical diagnoses dependent on their work. Unfortunately, these essential medical professionals are in short supply. With vacancy rates exceeding seven percent (up to 13.1 percent) for most categories of laboratory personnel, and anticipated retirement rates exceeding 20 percent within the next five years, the laboratory workforce will require significant corrective intervention to reverse this situation.(1)

The newly established Medical and Public Health Laboratory Workforce Coalition will work to draw attention to laboratory testing occupations and encourage individuals to consider careers in laboratory medicine, according to Bianca Frogner, PhD, Director of the University of Washington Center for Health Workforce Studies (UW CHWS). “Laboratory professionals serve critical roles in our nation’s health systems as highlighted during this pandemic. These can be excellent career opportunities, but we need to ensure these opportunities are known and accessible for all individuals, and that we support career progression to ensure diversity across the skill spectrum,” Dr. Frogner says.

The UW CHWS recently conducted a study examining the challenges and opportunities to build up the workforce. “The number of individuals entering the medical laboratory workforce is falling short of current and projected future needs,” says Dr. Frogner. “With impact of the pandemic on increasing work demands while burning out workers, laboratories across the United States are reporting workforce shortages, which poses a threat to quality care. Now is the time for collective attention of the entire laboratory and medical field.”

This new workforce coalition will work to increase visibility of the laboratory occupations, such as by exposing students from elementary school through college levels to the laboratory careers; expand and improve workforce recruitment, development, and retention efforts; and increase diversity, equity, and inclusion in the laboratory workforce.

As the Coalition embarks on this new task, we welcome those interested in joining the effort to address laboratory personnel shortages. Express your support to the laboratory and follow our progress as we tackle this problem. For more information and a list of the groups involved in this new coalition, click on https://www.mphlcoalition.org/

###

1. The American Society for Clinical Pathology 2020 Vacancy Survey of Medical Laboratories in the United States, Edna Garcia, MPH, Iman Kundu, MPH, Melissa Kelly, PhD, Ryan Soles, MS. American Journal of Clinical Pathology, Volume 157, Issue 6, June 2022, Pages 874–889, https://doi.org/10.1093/ajcp/aqab197.

Share article on social media or email:

Get Ready to Grow – Autofloweringcannabisseeds.org Now Offers Gorilla Glue Seeds


These seeds have been hand-selected for their superior genetics and will give growers an excellent starting point for producing top-notch cannabis plants with great yields of potent buds that will bring them great satisfaction and enjoyment.

Autoflowering Cannabis Seeds is proud to announce the arrival of their Gorilla Glue seeds. These Gorilla Glue seeds are 100% GG4 genetics and have been carefully selected for their strong genetics and ability to produce healthy plants with high yields of potent buds. The seeds are guaranteed to germinate, giving growers the assurance they need when choosing this strain for their next project.

“We’re thrilled to be able to offer our customers the highest quality Gorilla Glue seeds,” says CEO of Autofloweringcannabisseeds.org, Sim W. “These seeds have been hand-selected for their superior genetics and will give growers an excellent starting point for producing top-notch cannabis plants with great yields of potent buds that will bring them great satisfaction and enjoyment.”

Gorilla Glue is known for its strong aroma and potency, making it a favorite among many cannabis users. It has a pungent taste with hints of coffee and diesel fuel that make it stand out from other strains on the market today. It also has a very high THC content ranging from 18-25%, making it one of the most powerful strains available today.

Autofloweringcannabisseeds.org offers free shipping in the United States on all orders, so buyers can save even more when stocking up on Gorilla Glue seeds. They also offer secure payment options, including credit card payments as well as PayPal checkout options, so customers can purchase with confidence, knowing that their information is safe and secure at all times.

For those looking for top quality Gorilla Glue genetics at an affordable price, look no further than Autofloweringcannabisseeds.org. With fast shipping times, secure payment options, and unbeatable prices – they have everything you need to get started growing as soon as possible.

For more information, visit http://www.autofloweringcannabisseeds.org.

Share article on social media or email:

Reell Precision Manufacturing Names Shari Erdman as Co-CEO


News Image

Most importantly, [Shari] has the right heart and mind to lead the company into even more success in the future.

Reell Precision Manufacturing, a world leader in innovative small package motion control, is pleased to announce that Shari Erdman has been promoted to the position of Co-CEO. She will share leadership responsibilities with longtime Reell CEO Kyle Smith.

Shari joined Reell in 2004 and has worked in many areas of the company including accounting, customer service, office administration, and Coworker Services. In these roles she has served in multiple capacities including sourcing, customer account management, accounting support, manufacturing process improvements, Coworker Services management, quality, and overall office administration. She also served in the position of Executive Administrative Assistant where she had opportunity to engage in the operation of the entire company. Shari served the greatest portion of her career at Reell as the VP of Global Coworker Services (HR) and for the last 14 months has served as Reell’s President.

Reell’s Board Chair Michael Naughton is pleased to have Shari in her new role. “The Board of Directors unanimously agrees that Shari is the right leader for the company, and we are delighted to see her grow her skill set and exhibit her leadership across the company. Since joining Reell Shari has served Reell in many capacities, which give her a broad understanding of Reell’ business and culture. Shari has the longest tenure of anyone on the current leadership team. Most importantly, she has the right heart and mind to lead the company into even more success in the future.”

Shari holds an MBA and a Bachelor of Science in Business Administration from the University of Northwestern. She is an active member of the Chief Executive Network, has been very active with Manufacturer’s Alliance, Women in Manufacturing (WiM), as well as other local organizations including the Midwest ESOP chapter. Shari is a native of Minnesota and will continue to serve all Reell stakeholders from Reell’s corporate headquarters in Saint Paul.

Reell Precision Manufacturing provides high-quality innovative motion control and positioning control solutions to transmit torque, control angular position and protect delicate components from excessive force. Combining the world’s most precisely controlled torque technology with the industry’s most experienced engineering team provides a perfect product fit in customer applications. Reell’s patented technology is widely used in automotive, aircraft interiors, medical technology, workstation furniture, kiosk/data terminal, consumer electronics and architectural lighting industries.

Share article on social media or email:

Operations Strategist, Paul Wann, Named Chief Operating Officer at HPI


HPI, a leading national third-party administrator (TPA) of self-funded benefits, has tapped Paul Wann as their new chief operating officer. Paul will join senior leadership to drive the advancement of operations, automation, and programming. He brings over 30 years of experience in the industry, specializing in numerous areas including system configuration, member care, compliance, and analytics.

“Paul has an impressive background in the TPA industry and brings vital skills to HPI in both operations and programming,” said Deb Hodges, President and CEO. “I am confident he will become an essential part of our team as we continue our success as a national TPA.”

Paul most recently served as senior vice president of TPA solutions at Centivo, where he established TPA operations and served as the company’s industry subject matter expert. Previously, he served as chief operating officer at Consociate Health.

“HPI has an outstanding reputation in the industry as a highly respected TPA,” said Wann. “Known for their emphasis on client satisfaction over profit margins, decades of experience and expertise, and having a compassionate culture that extends to their employees, HPI aligns with my values. I’m grateful for the opportunity to join a great team, share knowledge and build on my experience.”

About HPI

HPI redefines what is possible with self-funded health plans. As a leading national third-party administrator, they partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each client’s needs and population. HPI’s solutions give employers greater cost transparency and control, while elevating the member experience. It is their flexible approach, entrepreneurial spirit and commitment to quality, technology, and service that enable them to deliver premium value to their customers. For more information, visit http://www.hpiTPA.com

Share article on social media or email:

Abdominal Core Health Quality Collaborative Celebrates Hernia Awareness Month With New Verified Surgeon of Quality Program


The Abdominal Core Health Quality Collaborative (ACHQC) is celebrating Hernia Awareness Month with the launch of its new Verified Surgeon of Quality Program. The goal of the ACHQC Verified Surgeon of Quality program is to recognize and distinguish participating surgeons for their dedication to improving the quality and value of health care for patients who suffer from hernia disease and diseases of the abdominal wall or abdominal core.

“ACHQC leadership believes surgeons focusing on quality improvement efforts will perform at their highest level,” shared Michael Rosen, MD, ACHQC Medical Director. “We hope that through this verification program, surgeons will be recognized by their peers and broader network for their dedication to improving the quality and value of patient care in their communities.”

ACHQC Verified Surgeons of Quality demonstrate a commitment to consistent entry of data in the ACHQC Registry and participation in ACHQC’s continuous quality improvement programs including the annual ACHQC QI Summit. Importantly, patients recognize that surgeons who focus on optimizing hernia surgical outcomes can provide an enhanced level of care.

“I’m really impressed by the efforts of the ACHQC surgeons” shared John Parker, one of the dedicated patient representatives serving on the ACHQC Patient Engagement and Advocacy Committee. “My advice to other patients is to find a surgeon who specializes in hernias who you feel comfortable with.”

For more information about the ACHQC Foundation, including a list of current ACHQC Verified Surgeons of Quality, visit http://www.achqc.org.

Abdominal Core Health Quality Collaborative programs are supported by Foundation Partners Medtronic, BD-Bard, Integra LifeSciences, TELA Bio, Allergan Aesthetics, Ethicon, Inc., and W.L. Gore.

About the ACHQC: Founded in 2013, the Abdominal Core Health Quality Collaborative (ACHQC) is a 501(c)(3) nonprofit foundation dedicated to maximizing the quality and value of care delivered to patients with hernias and other abdominal core diseases. The ACHQC has developed and manages a robust real-world data registry that securely houses the nation’s largest repository of real-world data on clinical outcomes related to hernia and abdominal core surgeries. The ACHQC is a CMS Qualified Clinical Data Registry and is an authoritative resource for organizations to assess quality metrics and demonstrate a commitment to efficient, value-based patient centered care. Participation in the ACHQC is free to surgeons and fulfills Part 4 of the American Board of Surgery Maintenance of Certification Program.

Share article on social media or email: